An observational study in Constipation and Pregnancy, sponsored by Takeda. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Constipation by Takeda — none open to participants now, 2 under way, none of them phase 3. Constipation · Takeda.
Among the 29 studies in Constipation by Takeda, this one is the only one that started in 2022, is one of 2 observational ones, and was the 29th registered.
1,048 studies on the registry are indexed under Constipation; 163 are open to participants now.
Browse Constipation studies →None of the 29 studies in Constipation by Takeda is open now. The open studies under Constipation, anywhere →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 44 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 120 across 126 observational studies indexed under Constipation.
Median enrollment 211 across the 27 interventional studies, 113 across the 2 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
2 of the studies in Constipation by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04869280TakedaPost-Marketing Study of Prucalopride Safety In Pregnancy | 2027-02-01 |
| NCT04961840TakedaA Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Constipation by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will collect information on pregnant women diagnosed with constipation from the two large health care insurance claims records.
It will include the following groups:
The main aim of the study is to find out whether the medicine prucalopride, which is used to treat constipation, is safe for use during pregnancy and to look at whether taking prucalopride at certain times during pregnancy is associated to a higher chance of specific health problems for the mother or baby.
The study uses two large existing healthcare insurance databases for collecting information. Participants are not enrolled, treated, or required to visit the doctor during this study.
The criteria were revised on the registry on Oct 13, 2026. See what changed
This study will include pregnancy women with constipation including those with constipation predominant irritable bowel syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Maternal coverage by health care and prescriptions insurance during eligibility period:
a) To study pregnancy outcomes (live births, spontaneous abortions, terminations, or stillbirths): 90 days prior to the LMP until end of pregnancy; and b) to study malformations, perinatal, and infant outcomes: 90 days to LMP until 30 days post-delivery.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women with clinically diagnosis of constipation who have been exposed to prucalopride during pregnancy will be observed.
Other: No Intervention
Pregnant women with clinical diagnosis of constipation who have been exposed to other constipation drugs and not prucalopride during pregnancy will be observed.
Other: No Intervention
Pregnant women with clinical diagnosis of constipation with no recorded prescription dispensed for any constipation drugs during pregnancy will be observed.
Other: No Intervention
This is a non-interventional study.
Percentage of Infants With Major Congenital Malformations
A major congenital malformation is defined as a structural abnormality with surgical, medical, or cosmetic importance. Major malformations will be sorted and grouped according to the International Classification of Diseases 10th Revision (ICD-10). Percentage of infants with major congenital malformations after birth will be reported.
Time frame: From delivery up to 90 days post-delivery
Percentage of Participants With Spontaneous Abortions
Spontaneous abortions will be defined as spontaneous losses before 20 weeks of gestation. Percentage of participants with spontaneous abortion will be reported.
Time frame: 90 days prior to the Last menstrual period (LMP) until end of pregnancy
Percentage of Participants With Terminations (Discontinuation of Pregnancy)
Percentage of participants with discontinuation of pregnancy through medication or surgical procedures will be reported.
Time frame: 90 days prior to the LMP until end of pregnancy
Percentage of Participants With Stillbirths
Stillbirths will be defined as in utero fetal deaths at or after 20 weeks of gestation. Percentage of participants with stillbirths will be reported.
Time frame: 90 days prior to the LMP until end of pregnancy
Percentage of Participants With Preterm Delivery
Preterm delivery is defined as a live birth occurring at less than (\<) 37 gestational weeks.
Time frame: From Delivery to 30 days post-delivery
Percentage of Infants With Small for Gestational Age (SGA)
SGA will be defined as weight at birth of full and preterm live-born infants in \<10th percentile. Percentage of infants with SGA will be reported.
Time frame: From Delivery to 30 days post-delivery
Percentage of Infants With Neonatal Intensive Care Unit (NICU) Admission
Percentage of infants admitted to NICU in relation to early and late pregnancy. exposure to prucalopride will be reported.
Time frame: From Delivery to 30 days post-delivery
Percentage of Infants With Hospitalizations
Percentage of infants With Hospitalizations during the first year of life in relation to prenatal exposure to prucalopride will be reported.
Time frame: From Delivery to 365 days post-delivery
Percentage of Infants With Poor Growth and Developmental Delays or Disorders
Percentage of infants With Poor Growth and developmental delays or disorders during the first year of life in relation to prenatal exposure to prucalopride will be reported.
Time frame: From Delivery to 365 days post-delivery
Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Started Jan 2022 (actual). Primary completion is estimated for Jun 2027, 65 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.